Lapatinib Tablet, Film Coated
Product Images NDC 42291-035

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lapatinib (NDC 42291-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (135 15)

Label for Lapatinib Tablets 250 mg by AvKARE, containing 150 film-coated tablets. The label includes dosage information, storage instructions, and a barcode. The product is prescription-only and the labeler NDC is 42291-035-15.*

FDA Label Image

Chemical Structure (Image 1)

Chemical structure diagram of Lapatinib, showing the molecular arrangement including aromatic rings, nitrogen atoms, and functional groups such as sulfonamide and ether moieties, consistent with the active ingredient Lapatinib in the drug product.*

FDA Label Image

Figure 1 (Image 2)

A Kaplan-Meier curve comparing cumulative progression-free survival over time in weeks for two treatment groups: Lapatinib (1,250 mg) plus Capecitabine (2,000 mg/m²) and Capecitabine alone (2,500 mg/m²). The vertical axis shows the proportion of patients progression-free, and the horizontal axis shows time in weeks.*

FDA Label Image

Figure 2 (Image 3)

A line graph showing cumulative progression-free survival over time (weeks) for two treatment groups: Lapatinib (1,250 mg) plus Capecitabine (2,000 mg/m²) and Capecitabine alone (2,500 mg/m²). The vertical axis represents cumulative progression-free rate, while the horizontal axis represents time in weeks up to 100 weeks. The combined therapy group shows a higher cumulative progression-free rate over time compared to Capecitabine alone.*

FDA Label Image

Figure 3 (Image 4)

A Kaplan-Meier curve illustrating cumulative progression-free survival over time (in weeks). The graph compares two treatments: Lapatinib (1,500 mg) plus Letrozole (2.5 mg) represented by a solid line, and Letrozole (2.5 mg) alone represented by a dashed line. The vertical axis shows progression-free survival probability from 0 to 1, and the horizontal axis shows time up to approximately 220 weeks.*

FDA Label Image

Figure 4 (Image 5)

A Kaplan-Meier survival curve showing cumulative progression-free survival over time in months since randomization for three treatment groups: Lapatinib (1,000 mg) plus Trastuzumab plus AI, Lapatinib (1,500 mg) plus AI, and Trastuzumab plus AI. The y-axis represents cumulative progression-free survival, ranging from 0 to 1.0, and the x-axis represents time in months up to 45.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.